Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Director departure
|
|
Zivo Bioscience, Inc. (ZIVO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/03/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/17/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"Form of Placement Agent Agreement",
"Form of Series A Common Warrant",
"Form of Series B Common Warrant",
"Form of Pre-Funded Warrant",
"Opinion of Fennemore Craig, P.C",
"Opinion of Honigman LLP",
"Form of Securities Purchase Agreement, by and between Zivo Biosciences, Inc. and the Investor",
"ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market" |
|
| 07/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/28/2023 |
RW
| Form RW - Registration Withdrawal Request: |
| 06/15/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Note",
"Warrant",
"Subscription Agreement",
"ZIVO Bioscience Receives $1 Million Bridge Financing BLOOMFIELD HILLS, Mich. – Zivo Bioscience, Inc. , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief Executive Officer, and President, John Payne. The loan carries 10% simple interest, may be prepaid without penalty, is extendable for an additional six months and includes warrants to purchase 390,000 shares of ZIVO common stock with a strike price of $2.91 per share. More information on the loan and warrants is available in ZIVO’s Form 8-K filed today with the SEC. ZIVO Bioscience intends to use the proceeds from this bridge financing for working capital ..." |
|
| 03/22/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 02/14/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/10/2023 |
8-K
| Quarterly results |
| 11/29/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/23/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/03/2022 |
8-K
| Quarterly results |
| 07/07/2022 |
8-K
| Quarterly results |
| 07/05/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/28/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/02/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/25/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq BLOOMFIELD HILLS, Mich., – ZIVO Bioscience, Inc. , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it received a Notice from Nasdaq that the Company has regained compliance of Nasdaq Listing Rule 5250. On April 19, 2022, the Company received a standard notice of noncompliance from Nasdaq indicating that, as a result of not having timely filed its Annual Report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission the Company was not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of all required periodic fina..." |
|
| 04/22/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 04/15/2022 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 03/01/2022 |
8-K/A
| Quarterly results |
| 02/25/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|